CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Convertible Preferred Stock	Common Stock Class A Common Stock	Common Stock Class B Common Stock	Additional Paid-In Capital	Accumulated Deficit	Class A Common Stock	Class B Common Stock	Total
Convertible Preferred Stock, Balance at beginning of the period at Dec. 31, 2020	$ 360,937
Convertible Preferred Stock, Balance at beginning of the period (in shares) at Dec. 31, 2020	107,197,118
Increase (Decrease) in Convertible Preferred Stock
Conversion of convertible preferred stock	$ (360,937)
Conversion of convertible preferred stock (in shares)	(107,197,118)
Balance at beginning of the period at Dec. 31, 2020		$ 1		$ 32,874	$ (394,806)			$ (361,931)
Balance at beginning of the period (in shares) at Dec. 31, 2020		6,593,291
Increase (Decrease) in Stockholders' Equity
Net loss					(3,632)			(3,632)
Common stock issued upon exercise of stock options		$ 1		11,688				11,689
Common stock issued upon exercise of stock options (in shares)		5,302,472
Common stock issued upon vesting of restricted stock units (in shares)		467,234
Conversion of convertible preferred stock		$ 8	$ 3	360,926				360,937
Conversion of convertible preferred stock (in shares)		80,770,178	26,426,937
Conversion of convertible debt		$ 1		49,916				49,917
Conversion of convertible debt (in shares)		5,115,140
Net equity infusion from the Business Combination		$ 6		361,281				361,287
Net equity infusion from the Business Combination (in shares)		69,228,811
Stock-based compensation expense				28,085				28,085
Balance at end of the period at Jun. 30, 2021		$ 17	$ 3	844,770	(398,438)			446,352
Balance at end of the period (in shares) at Jun. 30, 2021		167,477,126	26,426,937
Balance at beginning of the period at Mar. 31, 2021		$ 16	$ 3	831,640	(395,496)			436,163
Balance at beginning of the period (in shares) at Mar. 31, 2021		164,862,470	26,426,937
Increase (Decrease) in Stockholders' Equity
Net loss					(2,942)			(2,942)
Common stock issued upon exercise of stock options		$ 1		5,375				5,376
Common stock issued upon exercise of stock options (in shares)		2,147,422
Common stock issued upon vesting of restricted stock units (in shares)		467,234
Stock-based compensation expense				7,755				7,755
Balance at end of the period at Jun. 30, 2021		$ 17	$ 3	844,770	(398,438)			446,352
Balance at end of the period (in shares) at Jun. 30, 2021		167,477,126	26,426,937
Balance at beginning of the period at Dec. 31, 2021		$ 17	$ 3	874,886	(427,215)			447,691
Balance at beginning of the period (in shares) at Dec. 31, 2021		171,613,049	26,426,937			171,613,049	26,426,937
Increase (Decrease) in Stockholders' Equity
Net loss					(80,278)			(80,278)
Common stock issued upon exercise of stock options				810				810
Common stock issued upon exercise of stock options (in shares)		343,667
Common stock issued upon vesting of restricted stock units				(106)				(106)
Common stock issued upon vesting of restricted stock units (in shares)		859,816
Stock-based compensation expense				18,572				18,572
Balance at end of the period at Jun. 30, 2022		$ 17	$ 3	894,162	(507,493)			386,689
Balance at end of the period (in shares) at Jun. 30, 2022		172,816,532	26,426,937			172,816,532	26,426,937
Balance at beginning of the period at Mar. 31, 2022		$ 17	$ 3	884,336	(471,692)			412,664
Balance at beginning of the period (in shares) at Mar. 31, 2022		172,523,557	26,426,937
Increase (Decrease) in Stockholders' Equity
Net loss					(35,801)			(35,801)
Common stock issued upon exercise of stock options				159				159
Common stock issued upon exercise of stock options (in shares)		79,651
Common stock issued upon vesting of restricted stock units (in shares)		213,324
Stock-based compensation expense				9,667				9,667
Balance at end of the period at Jun. 30, 2022		$ 17	$ 3	$ 894,162	$ (507,493)			$ 386,689
Balance at end of the period (in shares) at Jun. 30, 2022		172,816,532	26,426,937			172,816,532	26,426,937